dinaciclib and Kidney-Neoplasms

dinaciclib has been researched along with Kidney-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for dinaciclib and Kidney-Neoplasms

Article	Year
Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with Cell cycle (Georgetown, Tex.), 2022, Volume: 21, Issue:10 Clear cell renal cell carcinoma (CC-RCC) remains one of the most deadly forms of kidney cancer despite recent advancements in targeted therapeutics, including tyrosine kinase and immune checkpoint inhibitors. Unfortunately, these therapies have not been able to show better than a 16% complete response rate. In this study we evaluated a cyclin-dependent kinase inhibitor, Dinaciclib, as a potential new targeted therapeutic for CC-RCC. Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cyclic N-Oxides; Cyclin-Dependent Kinase Inhibitor Proteins; Cyclin-Dependent Kinases; Female; Humans; Indolizines; Kidney Neoplasms; Male; Mice; Protein Kinase Inhibitors; Pyridinium Compounds; Synthetic Lethal Mutations; Von Hippel-Lindau Tumor Suppressor Protein	2022

Article

Year

Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with

Cell cycle (Georgetown, Tex.), 2022, Volume: 21, Issue:10

Clear cell renal cell carcinoma (CC-RCC) remains one of the most deadly forms of kidney cancer despite recent advancements in targeted therapeutics, including tyrosine kinase and immune checkpoint inhibitors. Unfortunately, these therapies have not been able to show better than a 16% complete response rate. In this study we evaluated a cyclin-dependent kinase inhibitor, Dinaciclib, as a potential new targeted therapeutic for CC-RCC.

Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cyclic N-Oxides; Cyclin-Dependent Kinase Inhibitor Proteins; Cyclin-Dependent Kinases; Female; Humans; Indolizines; Kidney Neoplasms; Male; Mice; Protein Kinase Inhibitors; Pyridinium Compounds; Synthetic Lethal Mutations; Von Hippel-Lindau Tumor Suppressor Protein

2022